uMotif and Xperiome, a global healthtech company specialising in rare disease are to collaborate through a partnership that will bring value to both life science companies conducting clinical trials and the patients participating in them, offering a new approach to patient recruitment through a community of motivated, research-ready patients and an industry-leading engagement platform to drive retention.
Clinical trial recruitment can take years and, globally, more than 85% of clinical trials fail to enroll on time. uMotif and Xperiome are joining forces to address the pain points that contribute to these delays, changing the paradigm in clinical trial recruitment by providing sponsors with the capabilities to match the right patients to the right studies, at the right time.
Specifically, the partnership will leverage Xperiome’s knowledge bank for the lived experience of rare disease to build a deep understanding of hard-to-reach populations. Xperiome combines these insights with a specialized matching engine, to connect research-ready members to clinical and real-world study opportunities. Then, once enrolled, uMotif’s patient-engagement app will capture large volumes of high quality ePRO, eDiary and symptom data in real-time throughout the duration of a clinical study. The easy-to-use uMotif app empowers patients to manage and collect their own data, increasing participants’ engagement in clinical research and understanding of their symptoms and behavior among trial sponsors.
Bruce Hellman, uMotif’s CEO said, “Having access to reliable patient data during clinical trials is crucial and it requires effective patient recruitment and engagement strategies. Xperiome and uMotif share a commitment to eliminating the friction in clinical trial enrollment, reducing the burden on both sites and participating patients. Our partnership is designed with patients in mind, to help sponsors and research professionals capture the best quality data in a way that suits study participants. It’s a win-win for all stakeholders and has the potential to aid in accelerating the delivery of vital therapies to patients who need them.”
Jeremy Edwards, Xperiome’s CEO said, “Finding and retaining eligible patients for trials is a significant challenge for pharma, especially in orphan drug research where populations are hard to reach and participation in research can add significant burdens for patients and their families. We are committed to providing more opportunity for rare disease patients to participate in clinical studies and our partnership with uMotif will deliver a better trial experience once enrolled. By working together, we will provide an end-to-end patient-focused solution that connects patients to research and supports them throughout their clinical trial journey.”
